Department of Epidemiology and Biostatistics, School of Public Health - Bloomington, Indiana University, Bloomington, IN, USA.
Department of Applied Health Science, School of Public Health - Bloomington, Indiana University, Bloomington, IN, USA.
Br J Cancer. 2014 Apr 2;110(7):1847-54. doi: 10.1038/bjc.2014.68. Epub 2014 Feb 25.
Epidemiological studies have reported that diabetes significantly increases overall mortality in patients with colorectal cancer. However, it is unclear whether diabetes increases colorectal cancer-specific mortality. We used the US Surveillance Epidemiology and End Results (SEER) database linked with Medicare claims data to assess the influence of pre-existing diabetes on prognosis of patients with colorectal cancer.
Data from 61,213 patients aged 67 or older with colorectal cancer diagnosed between 2003 and 2009 were extracted and prospectively followed through the date of death or the end of 2012 if the patient was still alive. Diabetes cases with and without complications were identified based on an algorithm developed for the Chronic Condition Data Warehouse (CCW). Cox models were used to estimate hazard ratios (HRs) for total mortality. The proportional subdistribution hazards model proposed by Fine and Gray was used to estimate HRs for colorectal cancer-specific mortality.
Compared with patients without diabetes, colorectal cancer patients with pre-existing diabetes had significantly higher risk of overall mortality (HR=1.20, 95 % confidence interval (95% CI): 1.17-1.23). The HR for overall mortality was more pronounced for patients who had diabetes with complications (HR=1.50, 95% CI: 1.42-1.58). However, diabetes was not associated with increased colorectal cancer-specific mortality after accounting for non-colorectal cancer outcomes as competing risk.
Pre-existing diabetes increased risk of total mortality among patients with colorectal cancer, especially among cancer patients who had diabetes with complications. The increased risk of total mortality associated with diabetes was primarily explained by increased cardiovascular-specific mortality, not by increased colorectal cancer-specific mortality.
流行病学研究报告称,糖尿病显著增加了结直肠癌患者的总死亡率。然而,糖尿病是否会增加结直肠癌特异性死亡率尚不清楚。我们使用美国监测、流行病学和最终结果(SEER)数据库与医疗保险索赔数据进行关联,以评估预先存在的糖尿病对结直肠癌患者预后的影响。
从 2003 年至 2009 年间诊断为结直肠癌且年龄在 67 岁或以上的 61213 例患者的数据被提取出来,并通过死亡日期或如果患者仍然存活则通过 2012 年底进行前瞻性随访。根据慢性疾病数据仓库(CCW)开发的算法,确定有无并发症的糖尿病病例。使用 Cox 模型估计总死亡率的风险比(HR)。使用 Fine 和 Gray 提出的比例亚分布风险模型估计结直肠癌特异性死亡率的 HR。
与没有糖尿病的患者相比,患有预先存在的糖尿病的结直肠癌患者的总死亡率风险显著更高(HR=1.20,95%置信区间(95%CI):1.17-1.23)。对于有并发症的糖尿病患者,总死亡率的 HR 更为明显(HR=1.50,95%CI:1.42-1.58)。然而,在考虑非结直肠癌结局作为竞争风险后,糖尿病与结直肠癌特异性死亡率的增加无关。
预先存在的糖尿病增加了结直肠癌患者的总死亡率风险,尤其是对于有并发症的癌症患者。与糖尿病相关的总死亡率增加的主要原因是心血管特异性死亡率增加,而不是结直肠癌特异性死亡率增加。